Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.61 AUD | 0.00% | -8.27% | +14.02% |
May. 15 | Recce Pharmaceuticals Doses First Patient in Urosepsis Rapid Infusion Clinical Trial | MT |
May. 10 | Recce Pharmaceuticals Finds 'Promising' Results From Nebulized RECCE 327 Pilot Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+14.02% | 83.16M | |
+32.36% | 709B | |
+30.77% | 595B | |
-1.60% | 367B | |
+20.07% | 334B | |
+6.04% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.27% | 171B |
- Stock Market
- Equities
- RCE Stock
- News Recce Pharmaceuticals Ltd
- Recce Pharmaceuticals Enters Deal with Etana Biotechnologies for Anti-Infective Portfolio Development; Shares Climb 7%